|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:oseltamivir
|
|
gptkbp:activities
|
neuraminidase inhibitor
|
|
gptkbp:age
|
not recommended for children under 2 weeks
|
|
gptkbp:appointed_by
|
oral capsule
oral suspension
|
|
gptkbp:approves
|
gptkb:1999
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Tamiflu
|
|
gptkbp:class
|
neuraminidase inhibitors
|
|
gptkbp:clinical_trial
|
Phase III
influenza prevention
acute influenza
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to oseltamivir
|
|
gptkbp:developed_by
|
gptkb:Gilead_Sciences
|
|
gptkbp:dosage_form
|
gptkb:beer
suspension
|
|
gptkbp:duration
|
5 days
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
powder for oral suspension
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Oseltamivir phosphate
|
|
gptkbp:indication
|
prophylaxis against influenza
|
|
gptkbp:ingredients
|
gptkb:oseltamivir
C16 H28 N2 O4 S
|
|
gptkbp:interacts_with
|
live attenuated influenza vaccine
probenecid
|
|
gptkbp:invention
|
gptkb:2016
|
|
gptkbp:is_available_on
|
generic version
|
|
gptkbp:is_used_for
|
treatment of influenza
|
|
gptkbp:lifespan
|
6 to 10 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
over 100 countries
|
|
gptkbp:metabolism
|
hepatically metabolized
|
|
gptkbp:pharmacokinetics
|
bioavailability 80%
|
|
gptkbp:safety_features
|
Category C
|
|
gptkbp:side_effect
|
headache
nausea
vomiting
diarrhea
neuropsychiatric events
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:treatment
|
reduces duration of flu symptoms
reduces risk of complications
|
|
gptkbp:type_of
|
198470-85-8
|
|
gptkbp:was_marked_by
|
gptkb:Tamiflu
|